Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of rational patient-controlled intravenous analgesia after general anesthesia surgery
ChiCTR2500098028Phase 4Not yet recruiting
- Sponsor
- Third People's Hospital of Hubei Province
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nalbuphine and sufentanil in postoperative pain (2 arms), sponsored by Third People's Hospital of Hubei Province. Primary endpoint: VAS pain score (resting and active). Planned start Feb 2025; status: not yet recruiting.
02
Drugs
nalbuphinesufentanil
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2500098028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098028.